Who are Busulphan plus Fludarabine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/busulphan-plus-fludarabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Busulphan plus Fludarabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Busulphan plus Fludarabine (Busulphan plus Fludarabine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating agent + Antimetabolite combination. Area: Oncology.

phase 3 Alkylating agent + Antimetabolite combination Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Busulphan plus Fludarabine (Busulphan plus Fludarabine) — Gruppo Italiano Trapianto di Midollo Osseo. Busulphan and Fludarabine together act as a myeloablative conditioning regimen that destroys bone marrow cells to prepare patients for hematopoietic stem cell transplantation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Busulphan plus Fludarabine TARGET	Busulphan plus Fludarabine	Gruppo Italiano Trapianto di Midollo Osseo	phase 3	Alkylating agent + Antimetabolite combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alkylating agent + Antimetabolite combination class)

Gruppo Italiano Trapianto di Midollo Osseo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Busulphan plus Fludarabine — Competitive Intelligence Brief. https://druglandscape.com/ci/busulphan-plus-fludarabine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing